Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...
PharmiWeb6d
Dialysis Market is Projected to Grow at 8% CAGR: Key Drivers and Challenges Ahead
The dialysis market is projected to grow at a CAGR of approximately 8% during the forecast period. This growth is driven by ...
The Pharma Letter4d
Strong Cresemba sales in Japan trigger first milestone payment to Basilea
Swiss drug developer Basilea Pharmaceutica reported that the sales of the antifungal Cresemba (isavuconazole) in Japan exceeded the threshold triggering the first sales milestone payment from its ...
Basilea Pharmaceutica AG: Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...
The Lancet6d
Applying the estimand framework to inflammatory bowel disease clinical trials
Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...
EuropaWire5d
Basilea’s Cresemba Achieves Key Sales Milestone in Japan and Strong Global Growth
Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 ...
DelveInsight Business Research, LLP: Global Biologics Drug Substance Manufacturing Market to Exhibit Growth at a CAGR of ~11% by 2032 | DelveInsight
The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics development ...
Medical Membrane Market Size, Share, Growth CAGR Of 10%
Medical Membrane Market was valued at USD 3.7 Bn in 2023. It is expected to reach USD 9.4 Bn by 2033, with a CAGR of 10%. Lawrence John Prudour +91 91308 55334 ...
朝日新聞社6d
Patients fear proposed hike in high-cost medical expense cap
Patients are voicing concerns as the government considers raising the monthly out-of-pocket cap on burgeoning medical expenses. Cancer patients who require long-term, costly treatments are ...